Literature DB >> 26355273

Riboflavin and ultraviolet A as adjuvant treatment against Acanthamoeba cysts.

Ricardo Lamy1, Elliot Chan1, Samuel D Good1, Vicky Cevallos2, Travis C Porco2, Jay M Stewart1.   

Abstract

BACKGROUND: Experimental studies have shown that the standard dose of riboflavin (R) or R + ultraviolet-A (UVA) as solo treatment are not able to exterminate Acanthamoeba cysts or even trophozoites. The purpose of this study is to determine whether the application of R + UVA can enhance the cysticidal effects of cationic antiseptic agents in vitro.
METHODS: The log of either polyhexamethylene biguanide or chlorhexidine minimal cysticidal concentration in solutions containing riboflavin (concentrations 0.1, 0.05 and 0.025%) plus either Acanthamoeba castellanii cysts or Acanthamoeba polyphaga cysts was determined and compared in groups treated with UVA 30 mW/cm(2) for 30 min and in control groups (with no exposure to UVA). A permutation test was used to determine the P value associated with treatment.
RESULTS: Regardless of the riboflavin concentration and UVA treatment condition, no trophozoites were seen in plates where the cysts were previously exposed to cationic antiseptic agent concentrations ≥200 µg/mL for Acanthamoeba castellanii samples and ≥100 µg/mL for A. polyphaga samples. There was no statistical evidence that R + UVA treatment was associated with minimal cysticidal concentration (P = 0.82).
CONCLUSION: R + UVA in doses up to 10 times higher than recommended for corneal crosslinking does not enhance the cysticidal effect of either polyhexamethylene biguanide or chlorhexidine in vitro.
© 2015 Royal Australian and New Zealand College of Ophthalmologists.

Entities:  

Keywords:  Acanthamoeba; photochemotherapy; riboflavin; ultraviolet

Mesh:

Substances:

Year:  2016        PMID: 26355273      PMCID: PMC4786490          DOI: 10.1111/ceo.12644

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  41 in total

1.  Increased resistance of crosslinked cornea against enzymatic digestion.

Authors:  Eberhard Spoerl; Gregor Wollensak; Theo Seiler
Journal:  Curr Eye Res       Date:  2004-07       Impact factor: 2.424

2.  Evaluation of in vitro efficacy of combined riboflavin and ultraviolet a for Acanthamoeba isolates.

Authors:  María A del Buey; José A Cristóbal; Paula Casas; Pilar Goñi; Antonio Clavel; Enrique Mínguez; Elena Lanchares; Alicia García; Begoña Calvo
Journal:  Am J Ophthalmol       Date:  2011-10-11       Impact factor: 5.258

Review 3.  Inactivation credit of UV radiation for viruses, bacteria and protozoan (oo)cysts in water: a review.

Authors:  W A M Hijnen; E F Beerendonk; G J Medema
Journal:  Water Res       Date:  2006-01       Impact factor: 11.236

Review 4.  Acanthamoeba keratitis: diagnosis and treatment update 2009.

Authors:  John K G Dart; Valerie P J Saw; Simon Kilvington
Journal:  Am J Ophthalmol       Date:  2009-08-05       Impact factor: 5.258

5.  Efficacy of novel antimicrobials against clinical isolates of opportunistic amebas.

Authors:  F L Schuster; G S Visvesvara
Journal:  J Eukaryot Microbiol       Date:  1998 Nov-Dec       Impact factor: 3.346

6.  Development and application of an in vitro susceptibility test for Acanthamoeba species isolated from keratitis to polyhexamethylene biguanide and chlorhexidine.

Authors:  Sandhya Narasimhan; Hajib N Madhavan; Lily Therese K
Journal:  Cornea       Date:  2002-03       Impact factor: 2.651

7.  Hydration behavior of porcine cornea crosslinked with riboflavin and ultraviolet A.

Authors:  Gregor Wollensak; Henning Aurich; Duy-Thoai Pham; Christopher Wirbelauer
Journal:  J Cataract Refract Surg       Date:  2007-03       Impact factor: 3.351

8.  Evaluation of antibacterial efficacy of photo-activated riboflavin using ultraviolet light (UVA).

Authors:  Karim Makdoumi; Anders Bäckman; Jes Mortensen; Sven Crafoord
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-11-18       Impact factor: 3.117

9.  Keratocyte apoptosis after corneal collagen cross-linking using riboflavin/UVA treatment.

Authors:  Gregor Wollensak; Eberhard Spoerl; Michaela Wilsch; Theo Seiler
Journal:  Cornea       Date:  2004-01       Impact factor: 2.651

10.  Corneal cross-linking and safety issues.

Authors:  Eberhard Spoerl; Anne Hoyer; Lutz E Pillunat; Frederik Raiskup
Journal:  Open Ophthalmol J       Date:  2011-02-11
View more
  4 in total

1.  Acanthamoeba Keratitis: an update on amebicidal and cysticidal drug screening methodologies and potential treatment with azole drugs.

Authors:  Brian Shing; Mina Balen; James H McKerrow; Anjan Debnath
Journal:  Expert Rev Anti Infect Ther       Date:  2021-05-19       Impact factor: 5.091

2.  High fluence PACK-CXL as adjuvant treatment for advanced Acanthamoeba keratitis.

Authors:  Mehrdad Nateghi Pettersson; Neil Lagali; Jes Mortensen; Victor Jofré; Per Fagerholm
Journal:  Am J Ophthalmol Case Rep       Date:  2019-06-20

3.  Treatment of recalcitrant Acanthamoeba Keratitis with Photoactivated Chromophore for Infectious Keratitis Corneal Collagen Cross-Linking (PACK-CXL).

Authors:  Shelly H Watson; Nakul S Shekhawat; Yassine J Daoud
Journal:  Am J Ophthalmol Case Rep       Date:  2022-01-22

4.  Evaluation of Amebicidal and Cysticidal Activities of Antifungal Drug Isavuconazonium Sulfate against Acanthamoeba T4 Strains.

Authors:  Brian Shing; Mina Balen; Anjan Debnath
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.